SCHEMBL16509095

SCHEMBL16509095

CC(C)CCCC(C)C1CCC2C3CC=C4CC(OC(=O)COCCOCCNC(=O)C(CCCCNC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C)CCC4(C)C3CCC12C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLA1 P09884 1/20 0.54
▸ CYP46A1 Q9Y6A2 2/20 0.53
▸ PLA2G2A P14555 1/20 0.50
▸ NR1H3 Q13133 3/20 0.48
▸ NPC1L1 Q9UHC9 5/20 0.48
▸ USP2 O75604 2/20 0.48
▸ OSBP P22059 2/20 0.48
▸ RORC P51449 2/20 0.48
▸ OSBP2 Q969R2 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ ABCB1 P08183 1/20 0.48
▸ GBA1 P04062 2/20 0.45
▸ UGCG Q16739 2/20 0.45
▸ GBA2 Q9HCG7 2/20 0.45
▸ NPC1 O15118 1/20 0.44
▸ CRYAB P02511 1/20 0.43
▸ HMGCR P04035 1/20 0.43
▸ ITGB3 P05106 1/20 0.43
▸ ITGAV P06756 1/20 0.43
▸ SREBF2 Q12772 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16509091 0.93 POLA1 (0.62) POLA1CYP46A1PLA2G2ANR1H3NPC1L1
SCHEMBL13363899 0.89 POLA1 (0.55) POLA1CYP46A1PLA2G2ANR1H3NPC1L1
SCHEMBL15007261 0.88 POLA1 (0.60) POLA1CYP46A1PLA2G2ANR1H3NPC1L1
SCHEMBL12989063 0.88 POLA1 (0.60) POLA1CYP46A1PLA2G2ANR1H3NPC1L1
SCHEMBL3514954 0.88 POLA1 (0.60) POLA1CYP46A1PLA2G2ANR1H3NPC1L1
SCHEMBL3514956 0.88 POLA1 (0.60) POLA1CYP46A1PLA2G2ANR1H3NPC1L1
SCHEMBL17665326 0.88 POLA1 (0.63) POLA1CYP46A1PLA2G2ANR1H3NPC1L1
SCHEMBL15702072 0.88 POLA1 (0.63) POLA1CYP46A1PLA2G2ANR1H3NPC1L1
SCHEMBL26032472 0.88 POLA1 (0.63) POLA1CYP46A1PLA2G2ANR1H3NPC1L1
SCHEMBL13363961 0.87 POLA1 (0.55) POLA1CYP46A1PLA2G2ANR1H3NPC1L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110305769-A1 BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM ENZON PHARMACEUTICALS, INC. (US) 2011-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110305769-A1 BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM NPC1L1, CETP, SREBF2 POLA1 1271/4885CYP46A1 55/4885PLA2G2A 497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback